Notably, decitabine can significantly increase ROS levels and promote the release of iron ions in MDS cells, which further generates reactive oxygen species through the Fenton reaction, thus exacerbating oxidative stress; as a consequence, decitabine reduces GSH levels and inhibits GPX4 activity, leading to the accumulation of lipid peroxides. Here, GPX4 is linked to myelodysplastic syndrome.